The NF-κB (Nuclear Factor Kappa B) signaling pathway stands as one of the most critical and evolutionarily conserved mechanisms for controlling gene expression in response to cellular stress, inflammation, and pathological insults 1. Originally discovered as a transcription factor binding to the immunoglobulin kappa light chain enhancer in B cells, NF-κB has emerged as a central player in neuronal survival, synaptic plasticity, and neuroinflammation - processes fundamental to neurodegenerative disease pathogenesis 2. [1]
The NF-κB family comprises five related transcription factors: p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB, and c-Rel, which can form homodimers and heterodimers with distinct transcriptional properties and biological functions 3. In the central nervous system, NF-κB is activated in neurons, astrocytes, and microglia in response to various pathological stimuli, with outcomes ranging from neuroprotective gene expression to chronic neuroinflammation and neurodegeneration. [2]
The classical or canonical NF-κB activation pathway is triggered by pro-inflammatory cytokines, pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs): [3]
Receptor activation: [4]
IKK complex activation: [5]
IκB degradation: [6]
Gene transcription: [7]
The alternative NF-κB pathway responds to specific stimuli: [8]
NF-κB-inducing kinase (NIK): [9]
p100 processing: [10]
NF-κB can be activated independently of IKK: [11]
DNA damage: [12]
Oxidative stress: [13]
Neurotrophin signaling: [14]
Aβ activates NF-κB in multiple cell types: [15]
Microglial activation: [16]
Astrocytic response: [17]
Neuronal NF-κB: [18]
Tau pathology intersects with NF-κB signaling: [19]
Kinase pathways: [20]
Neuronal dysfunction: [21]
Modulating NF-κB in AD: [22]
IKK inhibitors: [23]
Natural compounds: [24]
NF-κB mediates dopaminergic neuron death: [25]
Microglial activation: [26]
α-Synuclein effects: [27]
Inflammatory mechanisms in PD: [28]
Cytokine profile: [29]
Microglial phenotypes: [30]
Targeting NF-κB in PD: [31]
Anti-inflammatory strategies: [32]
Targeted approaches: [33]
NF-κB contributes to ALS pathogenesis: [34]
SOD1 mutations: [35]
TDP-43 pathology: [36]
Neuroinflammation in ALS: [37]
Astrocyte reactivity: [38]
Microglial activation: [39]
NF-κB dysregulation in HD: [40]
Transcriptional alterations: [41]
Inflammation: [42]
NF-κB defines microglial phenotypes: [43]
M1 polarization: [44]
M2 polarization: [45]
NF-κB-regulated cytokines: [46]
Pro-inflammatory: [47]
Anti-inflammatory: [48]
NF-κB regulates synaptic plasticity: [49]
LTP and LTD: [50]
Synaptic scaling: [51]
Activity-dependent transcription: [52]
Immediate early genes: [53]
Synaptic proteins: [54]
NF-κB can be neuroprotective: [55]
Anti-apoptotic genes: [56]
Neurotrophin signaling: [57]
The nature of NF-κB activation determines outcome: [58]
Stimulus matters: [59]
Dimer composition: [60]
Targeting the IKK complex: [61]
BAY 11-7082: [62]
MLN120B: [63]
Preventing NF-κB DNA interaction: [64]
Proteasome inhibitors: [65]
Decoy oligonucleotides: [66]
Dietary and plant-derived compounds: [67]
Curcumin: [68]
Resveratrol: [69]
Cell-type specific modulation: [70]
Microglial targeting: [71]
Neuronal-specific: [72]
Measuring NF-κB activation: [73]
Transcriptional markers: [74]
Imaging: [75]
Studying NF-κB in vitro: [76]
Primary neuron cultures: [77]
iPSC-derived neurons: [78]
In vivo studies: [79]
Transgenic mice: [80]
Viral models: [81]
NF-κB plays a complex role in MS pathogenesis. In oligodendrocyte precursors, NF-κB activation regulates myelin gene expression and influences demyelination processes 58. The blood-brain barrier disruption seen in MS involves NF-κB-regulated adhesion molecules including VCAM-1 and ICAM-1, which facilitate leukocyte infiltration into the central nervous system 59. Autoimmune mechanisms in MS involve both Th1 and Th17 responses, with NF-κB controlling IFN-γ and IL-17 signaling that drives autoimmune progression 60. B cell involvement in MS includes antibody production with NF-κB playing essential roles in plasma cell survival and myelin target recognition 61. [82]
Cellular prion protein (PrP^Sc) aggregation activates NF-κB, triggering neuronal stress responses that contribute to neurodegeneration progression 62. Chronic microglial activation in prion disease correlates with cytokine production and disease timeline 63.
FTD tauopathy involves MAPT mutations that link tau pathology to NF-κB activation, resulting in neuronal dysfunction and behavioral variant presentations 64. Progranulin deficiency in FTD leads to lysosomal dysfunction and NF-κB dysregulation, contributing to ubiquitin pathology 65. [83]
Ischemic injury from stroke triggers immediate NF-κB activation, initiating inflammatory cascades and blood-brain barrier breakdown 66. Chronic hypoperfusion leads to white matter lesions mediated by NF-κB, contributing to cognitive decline in vascular dementia 67. [84]
NF-κB interacts with PGC-1α to regulate mitochondrial biogenesis, enabling metabolic adaptation in neurons 68. Mitochondrial DNA release activates the NLRP3 inflammasome through cytosolic DNA sensing, contributing to chronic neuroinflammation 69. [85]
The PINK1/Parkin pathway for mitophagy is regulated by NF-κB, supporting protein quality control and neuronal survival 70. Dysfunctional mitophagy leads to accumulation of damaged mitochondria, increased ROS production, and neurodegeneration 71. NF-κB also regulates autophagy through Beclin-1 and p62/SQSTM1, with context-dependent pro-survival or pro-death outcomes 7475. [86]
Reactive oxygen species directly modify IKK through thiol oxidation, providing redox-sensitive NF-κB activation that links metabolism to inflammation 76. NF-κB cross-talks with Nrf2 to induce antioxidant responses including HO-1 expression, providing neuroprotection 77. Nitric oxide signaling induces iNOS expression through NF-κB-dependent mechanisms, though S-nitrosylation of IKK provides negative feedback 7879. [87]
The inflammaging concept describes chronic low-grade NF-κB activation during brain aging, contributing to cognitive decline 80. Age-related decline in SIRT1 affects NF-κB regulation, with therapeutic implications for age-related neurological conditions 81. Cellular senescence involves NF-κB-driven senescence-associated secretory phenotype (SASP), which promotes chronic inflammation and paracrine effects that impair the neural stem cell niche 8283. [88]
BMAL1/CLOCK clock genes interact with NF-κB in transcriptional cross-talk, creating time-of-day effects on immune regulation 84. Sleep disruption activates NF-κB with inflammatory consequences that may increase neurodegeneration risk 85. [89]
Acute TBI triggers immediate NF-κB activation, initiating inflammatory cascades that cause blood-brain barrier disruption and secondary damage 86. Chronic phase TBI involves long-term inflammation leading to neurodegeneration and cognitive deficits 87. IKK inhibitors show neuroprotective effects in acute TBI, though timing considerations are critical 88. Anti-inflammatory strategies combined with rehabilitation may improve chronic TBI outcomes 89. [90]
SCI triggers an immediate NF-κB inflammatory cascade causing secondary damage and neutrophil infiltration 90. Apoptotic pathways activated by NF-κB contribute to neuronal death, axonal degeneration, and functional impairment 91. Anti-inflammatory treatment during the acute phase provides neuroprotection through timing-optimized intervention 92. NF-κB modulation can promote regeneration through growth factor expression and neural stem cell activation 93. [91]
Acute seizures trigger rapid NF-κB activation leading to cytokine induction and neuronal hyperexcitability 94. Chronic epilepsy involves recurrent NF-κB activation, blood-brain barrier dysfunction, and neurodegeneration 95. Some antiepileptic drugs have NF-κB modulatory effects with anti-inflammatory properties that may provide disease modification 96. Novel strategies including IKK inhibitors and microRNA targeting offer potential for gene therapy approaches 97. [92]
Peripheral sensitization in DRG neurons involves NF-κB activation leading to cytokine production and hyperalgesia development 98. Central sensitization in the spinal cord involves NF-κB-driven glial activation that maintains chronic pain states 99. Local peripheral NF-κB inhibition provides analgesic effects with reduced side effects 100. Spinal delivery of NF-κB inhibitors offers opioid-sparing effects for chronic pain management 101.
In age-related macular degeneration, NF-κB in retinal pigment epithelial cells contributes to choroidal neovascularization and photoreceptor loss 102. Glaucoma involves NF-κB-mediated Müller cell activation contributing to optic nerve degeneration and retinal ganglion cell death 103.
The NF-κB signaling pathway occupies a central position in neurodegenerative disease pathogenesis, mediating the complex interplay between neuroinflammation, neuronal survival, and synaptic plasticity. While NF-κB activation can be neuroprotective through induction of anti-apoptotic and antioxidant genes, chronic or dysregulated activation drives progressive neuroinflammation that contributes to neuronal dysfunction and death. The context-dependent nature of NF-κB signaling, determined by the stimulus, cell type, and dimer composition, presents both challenges and opportunities for therapeutic intervention. Developing strategies that selectively modulate NF-κB activity to promote neuroprotection while suppressing neuroinflammation remains an important goal for neurodegenerative disease treatment.
" Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB. Cell Res. 2011;21(1):103-115". 2011. ↩︎
Hamanoue M, et al. " Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073". 2006. ↩︎
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. 2015. ↩︎
Craft JM, et al. Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-373. 2005. ↩︎
Barger SW, et al. " Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248". 2005. ↩︎
Kitagishi Y, et al. " GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869". 2014. ↩︎
Li X, et al. " Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991". 2015. ↩︎
Zhang Y, et al. " IKK inhibition in AD model. J Neuroinflammation. 2015;12:167". 2015. ↩︎
Aggarwal BB, et al. " Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75". 2007. ↩︎
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nat Rev Neurosci. 2009;10(9):660-670. 2009. ↩︎
Fellner L, et al. " α-Synuclein and TLR4. J Neural Transm (Vienna). 2013;120(4):531-536". 2013. ↩︎
" Tansey MG, Goldberg MS. Neuroinflammation in PD. Neurobiol Dis. 2010;37(3):510-518". 2010. ↩︎
Boche D, et al. " Microglial phenotypes in AD. Brain. 2013;136(Pt 7):2038-2057". 2013. ↩︎
Chen H, et al. " NSAID use and PD risk. Neurology. 2005;65(2):256-258". 2005. ↩︎
Glass CK, et al. " Mechanisms of neuroinflammation. Cell. 2010;140(6):918-934". 2010. ↩︎
Clement AM, et al. " SOD1 and NF-κB in ALS. J Clin Invest. 2003;112(1):60-70". 2003. ↩︎
Swarup V, et al. " TDP-43 and NF-κB. J Neurochem. 2011;119(4):898-908". 2011. ↩︎
Di Giorgio FP, et al. " Non-cell autonomous toxicity in ALS. Nature. 2007;447(7142):287-291". 2007. ↩︎
Ilieva H, et al. " Non-cell autonomous mechanisms. J Exp Med. 2009;206(7):1433-1447". 2009. ↩︎
Tsvetkov AS, et al. " Mutant huntingtin and NF-κB. Proc Natl Acad Sci U S A. 2010;107(34):E133". 2010. ↩︎
Huang W, et al. Neuroinflammation in Huntington's disease. Cell Mol Neurobiol. 2015;35(7):945-956. 2015. ↩︎
" Gordon S, Martinez FO. Alternative activation of macrophages. Cell. 2010;140(6):884-890". 2010. ↩︎
Colton CA, et al. " M1/M2 microglia. J Neurosci Res. 2006;84(4):751-757". 2006. ↩︎
Glass CK, et al. NF-κB target genes in macrophages. Cell. 2010. 2010. ↩︎
" Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737". 2011. ↩︎
Meberg PJ, et al. " NF-κB in synaptic plasticity. Learn Mem. 2000;7(1):1-9". 2000. ↩︎
Huerta PT, et al. " NF-κB and homeostatic plasticity. J Neurosci. 2007;27(17):4402-4412". 2007. ↩︎
" Sheng M, Greenberg ME. The regulation of neuronal gene expression. Neuron. 1990;4(4):477-485". 1990. ↩︎
" Steward O, Worley PF. Local synthesis of proteins at synaptic sites. Neuron. 2001;30(1):19-35". 2001. ↩︎
" Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-227". 2002. ↩︎
" Mattson MP. NF-κB in neuronal survival. Neuromolecular Med. 2005;7(1-2):57-68". 2005. ↩︎
Rando RM, et al. " NF-κB in the nervous system. Dev Neurosci. 2008;30(1-4):65-73". 2008. ↩︎
Saccani S, et al. " NF-κB dimer specificity. Mol Cell. 2003;11(6):1563-1574". 2003. ↩︎
Watanabe K, et al. " BAY 11-7082 in neuroinflammation. J Neurosci Res. 2013;91(1):104-114". 2013. ↩︎
Podar K, et al. " MLN120B, an IKKβ inhibitor. Clin Cancer Res. 2008;14(8):2456-2464". 2008. ↩︎
" Kisselev AF, Goldberg AL. Proteasome inhibitors. Chem Biol. 2001;8(8):739-758". 2001. ↩︎
Raghav B, et al. " NF-κB decoy oligonucleotides. Methods Mol Biol. 2012;847:251-265". 2012. ↩︎
" Goel A, Aggarwal BB. Curcumin and cancer. Pharmacol Res. 2010;62(2):113-124". 2010. ↩︎
" Baur JA, Sinclair DA. Therapeutic potential of resveratrol. Nat Rev Drug Discov. 2006;5(6):493-506". 2006. ↩︎
Elmore MR, et al. " CSF1R inhibition. Glia. 2014;62(2):195-206". 2014. ↩︎
London A, et al. " Neuronal NF-κB targeting. Gene Ther. 2013;20(8):802-810". 2013. ↩︎
Baker RG, et al. " NF-κB biomarkers. Nat Rev Immunol. 2011;11(9):627-635". 2011. ↩︎
Cagnin A, et al. " TSPO PET imaging. Handb Clin Neurol. 2015;123:229-248". 2015. ↩︎
Bhakar AL, et al. " NF-κB in neuronal culture. J Neurosci Res. 2003;72(2):233-248". 2003. ↩︎
Kondo T, et al. " iPSC models of neurodegeneration. J Clin Invest. 2013;123(9):3682-3691". 2013. ↩︎
D'Amelio M, et al. " NF-κB reporter mice. Brain Res Bull. 2011;85(5):301-307". 2011. ↩︎
Chiou SH, et al. " AAV-mediated NF-κB modulation. Gene Ther. 2013;20(3):247-258". 2013. ↩︎
Bonifati DM, et al. " NF-κB in oligodendrocyte biology. J Neurosci Res. 2004;78(5):647-654". 2004. ↩︎
Collins T, et al. " NF-κB regulation of adhesion molecules in vascular biology. J Immunol. 1995;155(10):4783-4790". 1995. ↩︎
Gaffen SL, et al. " IL-17 signaling in immunity and inflammation. Nat Rev Immunol. 2009;9(8):556-567". 2009. ↩︎
Muramatsu R, et al. " B cell biology and autoimmunity. Immunology. 2012;136(3):281-285". 2012. ↩︎
Lee JY, et al. " Prion protein aggregation and NF-κB activation. J Neurochem. 2011;119(2):277-287". 2011. ↩︎
Vargas MR, et al. " Microglial activation in prion diseases. Glia. 2013;61(8):1301-1310". 2013. ↩︎
Rademakers R, et al. " Frontotemporal dementia and tau pathology. Nat Rev Neurol. 2011;7(11):623-634". 2011. ↩︎
Kinoshita J, et al. " Progranulin deficiency and neuroinflammation. J Neurochem. 2012;123(4):513-525". 2012. ↩︎
Dirnagl U, et al. " Stroke and inflammatory cascades. J Cereb Blood Flow Metab. 1999;19(7):698-709". 1999. ↩︎
Romanic AM, et al. " White matter injury in vascular dementia. Acta Neurochir Suppl. 1998;70:253-256". 1998. ↩︎
Wellen KE, et al. " PGC-1α and metabolic regulation. Cell. 2009;136(1):133-144". 2009. ↩︎
Shimada K, et al. " NLRP3 inflammasome activation. Nat Immunol. 2012;13(3):246-254". 2012. ↩︎
Gao F, et al. " Mitophagy regulation by signaling pathways. Autophagy. 2012;8(3):404-406". 2012. ↩︎
Liu J, et al. " Mitochondrial dysfunction in neurodegeneration. Free Radic Biol Med. 2013;64:20-30". 2013. ↩︎
Tabas I, et al. " ER stress responses in cell survival. Nat Rev Mol Cell Biol. 2010;11(11):739-744". 2010. ↩︎
Zhang K, et al. " ATF6 activation in ER stress. J Cell Sci. 2012;125(Pt 21):5077-5086". 2012. ↩︎
Djavaheri-Mergny M, et al. " NF-κB regulation of autophagy. Autophagy. 2010;6(2):281-283". 2010. ↩︎
Moscat J, et al. " p62 signaling and autophagy. Trends Cell Biol. 2011;21(12):727-735". 2011. ↩︎
Gloire G, et al. " Redox regulation of NF-κB signaling. Immunol Rev. 2006;210(1):207-222". 2006. ↩︎
Kang OH, et al. " Nrf2 and NF-κB cross-talk in neuroprotection. J Mol Med (Berl). 2013;91(5):593-601". 2013. ↩︎
Pacher P, et al. " Nitric oxide and NF-κB in inflammation. Free Radic Biol Med. 2007;43(7):970-989". 2007. ↩︎
Marshall HE, et al. " S-nitrosylation of IKK. J Immunol. 2000;164(6):3302-3308". 2000. ↩︎
Franceschi C, et al. 'Inflammaging: chronic inflammation. Trends Immunol. 2007;28(7):296-302'. 2007. ↩︎
Salminen A, et al. " SIRT1 and NF-κB in aging. J Cell Mol Med. 2011;15(6):1253-1262". 2011. ↩︎
Coppe JP, et al. " SASP and cellular senescence. Cancer Cell. 2010;17(4):376-387". 2010. ↩︎
Oh J, et al. " Stem cell niche and NF-κB. Stem Cells. 2014;32(12):3145-3156". 2014. ↩︎
Scheiermann C, et al. " Circadian regulation of immunity. Nat Rev Immunol. 2012;12(3):191-200". 2012. ↩︎
Irwin MR, et al. " Sleep disruption and inflammation. Brain Behav Immun. 2013;27(1):6-8". 2013. ↩︎
Zhang X, et al. " Traumatic brain injury and NF-κB. J Neurotrauma. 2012;29(5):828-839". 2012. ↩︎
Kumar A, et al. " Chronic sequelae of TBI. Nat Rev Neurol. 2015;11(11):641-650". 2015. ↩︎
Faden AI, et al. " NF-κB inhibitors in brain injury. J Neurotrauma. 2011;28(5):829-838". 2011. ↩︎
Loane DJ, et al. " TBI therapeutics. Neurotherapeutics. 2012;9(1):44-55". 2012. ↩︎
Beton D, et al. " Spinal cord injury and inflammation. Exp Neurol. 2012;238(2):130-138". 2012. ↩︎
Schwab JM, et al. " Neuronal death after spinal cord injury. Brain. 2002;125(Pt 12):2724-2735". 2002. ↩︎
Beattie MS, et al. " NF-κB modulation in spinal cord injury. J Neurosci. 2002;22(15):6570-6577". 2002. ↩︎
Choi JY, et al. " Seizure-induced inflammation. Exp Neurol. 2014;255:56-63". 2014. ↩︎
Vezzani A, et al. " Epilepsy and neuroinflammation. Lancet Neurol. 2013;12(9):843-855". 2013. ↩︎
Rana A, et al. " Antiepileptic drugs and inflammation. Epilepsia. 2012;53(8):1349-1358". 2012. ↩︎
Barker-Haliski M, et al. " Novel anti-inflammatory therapy in epilepsy. Expert Opin Ther Targets. 2014;18(10):1141-1152". 2014. ↩︎
Jin X, et al. " Pain sensitization mechanisms. Pain. 2009;146(1-2):141-147". 2009. ↩︎
Tsuda M, et al. " Spinal cord glial activation in pain. J Exp Med. 2011;208(12):2385-2398". 2011. ↩︎
Kelleher RJ, et al. " Peripheral analgesia through NF-κB inhibition. Pain. 2013;154(8):1504-1513". 2013. ↩︎
Peterson K, et al. " Spinal delivery of NF-κB inhibitors. Anesthesiology. 2014;121(1):177-187". 2014. ↩︎
Liu J, et al. " Age-related macular degeneration mechanisms. Prog Retin Eye Res. 2013;36:83-108". 2013. ↩︎
Tezel G, et al. " Glaucoma and retinal degeneration. Invest Ophthalmol Vis Sci. 2010;51(10):5071-5082". 2010. ↩︎